

Please type a plus sign (+) inside the box → ☐


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for rough 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

PTO/SB/21 (08-00)

078-177



# TRANSMITTAL FORM

(to be used for correspondence after initial filing)

Application Number	09/724,961
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1771
Examiner Name	Unassigned
Attorney Docket Number	015270J-004752US

Total Number of Pages in This Submission **38**

## ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form (1 page, in duplicate)
  - ☐ Fee Attached
- ☐ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request (1 page)
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):
  1. Communication Under 37 CFR § 1.821-1.825 and Preliminary Amendment (12 pp), w/ attached paper copy of Sequence Listing (22 pp);
  2. Request to Reference Previously Filed Identical Computer Readable Copy According to 37 CFR 1.821(e) (2 pp); and,
  3. Return Postcard.

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Rosemaria L. Celli	Reg No. 42,397
Signature	<i>Rosemaria L. Celli</i>	
Date	September 20, 2001	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: September 20, 2001

Typed or printed name	Wanda Alleje	Date	September 20, 2001
Signature	<i>Wanda Alleje</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3168325 v1

RECEIVE  
SEP 27 2001  
TO 1700

NOV 02 2001

RECEIVED

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Box SEQUENCE  
Washington, D.C. 20231

On September 20, 2001

TOWNSEND and TOWNSEND and CREW

By: Wanda Alleje

Wanda Alleje



Attorney Docket No.: 15270J-004752US  
Client Ref. No. 209-US-CIP8AC2

PATENT

#5/2  
11/25/01

RECEIVED

NOV 02 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schenk et al.

Application No.: 09/724,961

Filed: November 28, 2000

For: PREVENTION AND  
TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: UNASSIGNED

Art Unit: 1771

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

RECEIVED  
SEP 27 2001  
TC 1700

Box SEQUENCE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith the required paper and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

The paragraph beginning at page 7, line 32, has been amended as follows:

Fig. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide

a  
301